Choudhary Anshoo, Wishart Peter K
St. Paul's Eye Unit, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK.
Clin Exp Ophthalmol. 2007 May-Jun;35(4):340-7. doi: 10.1111/j.1442-9071.2007.01483.x.
To investigate the long-term efficacy and safety of non-penetrating glaucoma surgery (NPGS) augmented with mitomycin C (MMC) or 5-fluorouracil (5FU) in eyes at high risk of failure of glaucoma filtration surgery.
Prospective study of all eyes, undergoing NPGS with 0.04% MMC (1 to 2 min topical or 0.04 mL subconjunctival injection into the superior fornix) or 5FU (25 mg/mL topically for 5 min). Complete success was an intraocular pressure (IOP)<or=21 mmHg on no medication and qualified success an IOP<or=21 mmHg with topical medication. An additional criterion for success was a >or=20% drop in IOP or a reduction of at least two medications.
Twenty-three eyes of 22 patients with a mean follow up of 41.4 months were reviewed. Fifteen eyes had failed trabeculectomy and seven had uveitic glaucoma. Mean preoperative IOP reduced from 25.8+/-7.8 to 15.4+/-4.9 mmHg at final visit, a mean change of 41%. Median number of preoperative medications decreased from 3 to 0 postoperatively. Cumulative probability of success was 100% at 2 years, 94% at 3 years and 85% at 4 years. No patient developed any long-term complications. Complete success was achieved in 11 eyes and qualified success in 10 eyes. Two eyes failed and required further surgery.
NPGS augmented with small-volume MMC/5FU provides good long-term IOP control in eyes at high risk of failure with a lower incidence of complications compared with augmented trabeculectomy and eliminates the need for postoperative bleb or suture manipulation.
研究在青光眼滤过手术失败风险较高的眼中,使用丝裂霉素C(MMC)或5-氟尿嘧啶(5FU)增强的非穿透性青光眼手术(NPGS)的长期疗效和安全性。
对所有接受NPGS的眼睛进行前瞻性研究,使用0.04% MMC(1至2分钟局部应用或0.04 mL结膜下注射至上穹窿)或5FU(25 mg/mL局部应用5分钟)。完全成功定义为未使用药物时眼压(IOP)≤21 mmHg,合格成功定义为使用局部药物时IOP≤21 mmHg。成功的另一个标准是IOP下降≥20%或至少减少两种药物。
对22例患者的23只眼睛进行了回顾,平均随访41.4个月。15只眼睛小梁切除术失败,7只眼睛患有葡萄膜炎性青光眼。末次随访时,术前平均IOP从2(5.8±7.8)mmHg降至15.4±4.9 mmHg,平均变化为41%。术前药物中位数从3种降至术后0种。2年时成功的累积概率为100%,3年时为94%,4年时为85%。没有患者出现任何长期并发症。11只眼睛实现了完全成功,10只眼睛实现了合格成功。2只眼睛失败,需要进一步手术。
与增强小梁切除术相比,使用小剂量MMC/5FU增强的NPGS能在失败风险较高的眼中提供良好的长期眼压控制,并发症发生率较低,并且无需术后对滤过泡或缝线进行操作。